Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE SODIUM PRESERVATIVE FREE versus PYQUVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE SODIUM PRESERVATIVE FREE versus PYQUVI.
METHOTREXATE SODIUM PRESERVATIVE FREE vs PYQUVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), preventing the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with DNA synthesis, repair, and cellular replication. It also inhibits thymidylate synthase and purine biosynthesis, and has immunosuppressive and anti-inflammatory effects mediated by adenosine release.
Pyquvi (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-2α, promoting erythropoietin production and iron mobilization, thereby stimulating erythropoiesis.
15-25 mg once weekly orally or intramuscularly for rheumatoid arthritis; 50-75 mg/m2 once weekly intravenously for single-agent acute lymphoblastic leukemia maintenance; 50 mg/m2 intravenously every 2-4 weeks for ectopic pregnancy; 30-40 mg/m2 intravenously once weekly for psoriasis. Dosing varies by indication.
400 mg orally once daily with food, continued until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is 8-15 hours at standard doses; with high-dose therapy (>1 g/m²), half-life extends to 12-24 hours due to saturation of excretion pathways and potential third-space accumulation.
The terminal elimination half-life is approximately 50 hours (range 40–60 hours), supporting once-daily dosing. Steady-state is achieved within 2–3 weeks of continuous dosing.
Primarily renal (80-90% excreted unchanged via glomerular filtration and active tubular secretion). Biliary/fecal elimination accounts for <10%.
Primarily hepatic metabolism via CYP3A4 and UGT1A9, with less than 5% of the dose excreted unchanged in urine. Fecal excretion accounts for approximately 70% of total clearance, primarily as metabolites.
Category D/X
Category C
Antimetabolite
Antimetabolite